Saroja Pharma Industries India (NSE:SAROJA) EBIT : ₹24.9 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Saroja Pharma Industries India EBIT?

Saroja Pharma Industries India's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2024 was ₹24.9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹24.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Saroja Pharma Industries India's annualized ROC % for the quarter that ended in Mar. 2024 was 10.06%. Saroja Pharma Industries India's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 14.87%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Saroja Pharma Industries India's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 11.27%.

Saroja Pharma Industries India EBIT Historical Data

The historical data trend for Saroja Pharma Industries India's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Saroja Pharma Industries India EBIT Chart

Saroja Pharma Industries India Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

EBIT

13.01

22.46

24.87

Saroja Pharma Industries India Semi-Annual Data
	Mar21	Mar22	Mar23	Mar24
EBIT	13.01	22.46	24.87	24.87

Competitive Comparison of Saroja Pharma Industries India's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Saroja Pharma Industries India's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Saroja Pharma Industries India's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Saroja Pharma Industries India's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Saroja Pharma Industries India's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Saroja Pharma Industries India EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹24.9 Mil.

Saroja Pharma Industries India (NSE:SAROJA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Saroja Pharma Industries India's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	24.656 * ( 1 - 27.24% )	/	( (150.955	+	205.767)	/ 2 )
=	17.9397056	/	178.361
=	10.06 %

where

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	213.399	-	58.803	-	( 3.641	-	max(0, 134.292	-	161.491	+	3.641	))
=	150.955

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	265.624	-	56.639	-	( 3.218	-	max(0, 92.919	-	175.976	+	3.218	))
=	205.767

Note: The Operating Income data used here is one times the annual (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Saroja Pharma Industries India's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	24.873	/	( ( (40.025 + max(97.321, 0))	+	(86.386 + max(110.913, 0)) )	/	2 )
=	24.873	/	( ( 137.346	+	197.299 )	/	2 )
=	24.873	/	167.3225
=	14.87 %

where Working Capital is:

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(111.078	+	38.658	+	8.106)	-	(58.803	+	0	+	1.718)
=	97.321

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(162.402	+	3.977	+	6.309)	-	(56.639	+	0	+	5.136)
=	110.913

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Saroja Pharma Industries India's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	24.873	/	220.781
	=	11.27 %

Saroja Pharma Industries India EBIT Related Terms

Thank you for viewing the detailed overview of Saroja Pharma Industries India's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Saroja Pharma Industries India Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Saroja Pharma Industries India Ltd (NSE:SAROJA) » Definitions » EBIT

Traded in Other Exchanges

N/A

Address

Jata Shankar Dosa Marg, Shop No. 209, 2ND Floor, Ecstacy, City of Joy, Mulund west, Mumbai, MH, IND, 400080

Website

https://www.sarojapharma.com

Saroja Pharma Industries India Ltd is a company engaged in pharmaceutical and healthcare sector. The Company trades in Pharma Active Pharmaceutical Ingredients, Pharma Intermediates, Chemicals, Solvents used for pharmaceutical products human and veterinary medicines. The Company has only one reportable Business Segment which is Pharma Chemicals like Thionyl Chloride and Pharmaceuticals intermeddles etc.

Saroja Pharma Industries India Headlines

No Headlines